Stephen SundlofUnited States Food and Drug Administration This paper discusses the problem of making decisions based on science, without taking into consideration societal values. Science is value-neutral which is problematic if it is used as a sole guide to decision-making, as is…
James CoffmanKansas State University This paper summarizes and discussed National Research Council, Board on Agriculture and Natural Resources report (NRC, 1999) on the Use of Drugs in Food Animals: Benefits and Risks. In reflection of the report itself, it focuses on issues…
Ghislain FolletEuropean Federation of Animal Health Industries (FEDESA), Belgium A number of resistant bacterial pathogens have become the focus of recent concern in human medicine. Studies and facts on use of antibiotics in animals suggest that animal sources contribute little to the…
Robert CollierThe University of Arizona In the United States (US) and European Union (EU) the regulatory and commercialization process for recombinant bovine somatotropin (rbST) had widely differing outcomes. Although the regulatory process in both locations was completed in 1993 the commercialization of…
Dirk BrinckmanLiedekerke Siméon Wessing Houthoff, Belgium In December 1999, the Council of the European Union (EU) decided to definitively ban possible use of recombinant bovine somatotrophin (rBST) in the European Union. In support of its ban it invoked animal welfare reasons. Prior…
Stephen L. Ott and C. Matthew RendlemanCEAH & Southern Illinois University Based on a 1996 United States Department of Agriculture (USDA) survey of 1,178 dairy producers and a milk price of $13 per hundredweight (cwt), optimal recombinant bovine somatotropin (rBST) use would…
Bradford L. Barham, Douglas Jackson-Smith, and Sunung MoonUniversity of Wisconsin Adoption of rBST on Wisconsin dairy farms has been modest, and is limited by farm operations: (1) finding rBST disadvantageous given their moderate scale and lack of use of technologies and practices…
